Indoco Remedies Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹520 Cr +7.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
IR

Indoco Remedies

Q4 FY26Pharmaceuticals & Biotechnology

Indoco Remedies Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹476Cr
+22.1% YoY
+7% QoQ
Net profit
−₹24Cr
Q4 FY25: −₹41 Cr
Margin
10%
+10.2 pp YoY
+3 pp QoQ

Indoco Remedies Q4 FY26 key numbers

Revenue
Warren Remedies (India OTC): Business grown from INR 90-94 crore to INR 120-130 crore; expecting further growth with key brands and new product launches.

As stated in Indoco Remedies's Q4 FY26 earnings call transcript · published 18 Aug 2026. Reported figures, not investment advice.

Price₹226
Market cap₹2.0K Cr

The short version

India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well. Europe business and base contract manufacturing expected to grow with better margins due to completed MMP scale-ups.

From Indoco Remedies's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well.
  • Regulated Markets (Europe & US): Continued growth anticipated with better margins, especially from contract manufacturing; expansion into liquid oral products planned for FY '27-'28.
  • Emerging Markets: High confidence for growth in next 2-3 years driven by strong portfolio and active field force in Africa regions.
  • Warren Remedies (India OTC): Business grown from INR 90-94 crore to INR 120-130 crore; expecting further growth with key brands and new product launches.

2 more points from Indoco Remedies's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Indoco Remedies said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No major CAPEX is planned for the next 2 years as per Pramod Ghorpade's statement.
  • Current focus is on tight control of CAPEX and reducing operating expenses.
  • API plant has ongoing validations and capital expenditure already done, but no new significant investments are planned.

2 more points from Indoco Remedies's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Indoco Remedies said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - Europe business, especially base contract manufacturing, is expected to continue growing with better margins. - U.S. market growth driven by sterile products and a substantial portfolio of solid oral products. - Plans to launch liquid orals in Europe and U.S., expected to contribute to growth. - Emerging market business (Eastern Africa & French West Africa) has a strong product portfolio and field force, with confidence for growth over the next 2-3 years. - Warren Remedies has started exports (to South Africa) with initial small orders and is seeking further opportunities.

2 more points from Indoco Remedies's call on order book

Create a free account to keep reading this call

Indoco Remedies — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Indoco Remedies Q4 FY26 results — key figures

Indoco Remedies Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue476390+22.1%445+7%
Operating profit (EBITDA)50-1—32+56.3%
Operating margin10%-0.2%+10.2 pp7%+3 pp
Profit before tax-25-46—-31—
Net profit (PAT)-24-41—-29—
EPS (₹)-2.34-4.38—-3.23—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹520 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Indoco Remedies and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Indoco Remedies Q4 FY26 results?

India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well. Europe business and base contract manufacturing expected to grow with better margins due to completed MMP scale-ups.

What is Indoco Remedies share price analysis?

Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.

Is Indoco Remedies planning capital expenditure?

No major CAPEX is planned for the next 2 years as per Pramod Ghorpade's statement.

Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.